MeMed
MeMed is dedicated to transforming patient care by decoding the immune system's signals into actionable diagnostics. Their mission is to listen to the immune system and turn host response signals into clinical insights, helping clinicians make more informed treatment decisions, especially in infectious diseases and inflammatory disorders. They develop rapid, host-response diagnostic tests, including MeMed BV and MeMed Key, which leverage machine learning and biomarkers to differentiate bacterial from viral infections in just 15 minutes, thereby improving treatment accuracy, reducing antibiotic misuse, and supporting better patient outcomes. Their technology is pathogen-agnostic, detecting immune responses rather than specific pathogens, and has been validated in multiple independent studies and real-world clinical use on thousands of patients. The company’s performance metrics include an ROC-AUC of 97%, high sensitivity and specificity in suspected sepsis patients, and a low equivocal rate of 8-12%. They also provide extensive clinical validation, research publications, and real-world evidence supporting their diagnostic accuracy and utility in various clinical settings.
Industries
Nr. of Employees
medium (51-250)
Products
15-minute host-response infection differentiation test
Rapid semi-quantitative immunoassay measuring a multi-protein host-response panel and applying a machine-learning algorithm to generate a single score that indicates likelihood of bacterial versus viral infection from serum or venous whole blood within approximately 15 minutes.
Compact cartridge-based immunoassay analyzer
Small-footprint analyzer that runs multiplex chemiluminescence immunoassays from sealed single-use cartridges, enabling low-volume, high-sensitivity protein measurements at or near the point of care with laboratory connectivity and minimal maintenance.
Biomarker-based severity prognostic test (in development)
A prognostic immunoassay under development that integrates host-response biomarker measurements with machine-learning models to produce a numeric severity score indicating short-term risk of deterioration for patients with suspected acute infection or sepsis.
15-minute host-response infection differentiation test
Rapid semi-quantitative immunoassay measuring a multi-protein host-response panel and applying a machine-learning algorithm to generate a single score that indicates likelihood of bacterial versus viral infection from serum or venous whole blood within approximately 15 minutes.
Compact cartridge-based immunoassay analyzer
Small-footprint analyzer that runs multiplex chemiluminescence immunoassays from sealed single-use cartridges, enabling low-volume, high-sensitivity protein measurements at or near the point of care with laboratory connectivity and minimal maintenance.
Biomarker-based severity prognostic test (in development)
A prognostic immunoassay under development that integrates host-response biomarker measurements with machine-learning models to produce a numeric severity score indicating short-term risk of deterioration for patients with suspected acute infection or sepsis.
Services
Clinical implementation and training
On-site and remote implementation planning, clinical training for physicians and staff, workflow optimization, protocol and order-set support, and post-installation clinical follow-up.
Clinical evidence generation and educational dissemination
Support for multi-center clinical studies, pragmatic real-world evidence collection, peer-reviewed publications, conference abstracts, webinars and training materials to demonstrate diagnostic performance and clinical utility.
Workflow integration and operational consulting
Adoption guides, protocol alignment and operational modeling to integrate rapid diagnostics into sepsis and emergency department pathways, including analyses of potential cost savings and patient-flow impacts.
Partnerships and laboratory integration services
Collaborative engagements to adapt assays for high-throughput central-lab analyzers and to integrate diagnostic workflows with external laboratory platforms and partners.
Analytical verification and laboratory support
Provision of verification kits and on-site support for analytical verification studies (accuracy, precision, reportable range) to assist labs in meeting CLIA and local verification requirements.
Clinical implementation and training
On-site and remote implementation planning, clinical training for physicians and staff, workflow optimization, protocol and order-set support, and post-installation clinical follow-up.
Clinical evidence generation and educational dissemination
Support for multi-center clinical studies, pragmatic real-world evidence collection, peer-reviewed publications, conference abstracts, webinars and training materials to demonstrate diagnostic performance and clinical utility.
Workflow integration and operational consulting
Adoption guides, protocol alignment and operational modeling to integrate rapid diagnostics into sepsis and emergency department pathways, including analyses of potential cost savings and patient-flow impacts.
Partnerships and laboratory integration services
Collaborative engagements to adapt assays for high-throughput central-lab analyzers and to integrate diagnostic workflows with external laboratory platforms and partners.
Analytical verification and laboratory support
Provision of verification kits and on-site support for analytical verification studies (accuracy, precision, reportable range) to assist labs in meeting CLIA and local verification requirements.
Expertise Areas
- Host-response diagnostic development
- Point-of-care immunoassay platform engineering
- Multiplex protein immunoassay development
- Clinical diagnostic validation and real-world evidence generation
Key Technologies
- Host-response biomarker panel (TRAIL, IP-10, CRP)
- Chemiluminescence immunoassay detection
- Multiplex protein immunoassays
- Cartridge-based sealed consumables